- Record: found
- Abstract: not found
- Article: not found
Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history
Liona C. Poon ,
David Wright ,
Daniel L. Rolnik ,
Argyro Syngelaki ,
Juan Luis Delgado ,
Theodora Tsokaki ,
Gergo Leipold ,
Ranjit Akolekar ,
Siobhan Shearing ,
Luciana De Stefani ,
Jacques C. Jani ,
Walter Plasencia ,
Nikolaos Evangelinakis ,
Otilia Gonzalez-Vanegas ,
Nicola Persico ,
Kypros H. Nicolaides
November 2017
November 2017
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for
Evidence-Based Preeclampsia Prevention trial demonstrated that in women who were at
high risk for preterm preeclampsia with delivery at <37 weeks' gestation identified
by screening by means of an algorithm that combines maternal factors and biomarkers
at 11-13 weeks' gestation, aspirin administration from 11 to 14 until 36 weeks' gestation
was associated with a significant reduction in the incidence of preterm preeclampsia
(odds ratio 0.38; 95% confidence interval, 0.20 to 0.74; P=0.004).